Literature DB >> 11121615

Synthesis and in vitro opioid activity profiles of DALDA analogues.

P W Schiller1, T M Nguyen, I Berezowska, S Dupuis, G Weltrowska, N N Chung, C Lemieux.   

Abstract

The tetrapeptide DALDA (H-Tyr-D-Arg-Phe-Lys-NH2) is a polar and selective mu agonist showing poor penetration of the placental and blood-brain barriers. In an effort to enhance the potency of DALDA, analogues containing 2',6'-dimethyltyrosine (Dmt), N,2',6'-trimethyltyrosine (Tmt), 2'-methyltyrosine (Mmt) or 2'-hydroxy,6'-methyltyrosine (Hmt) in place of Tyr1, or Orn or alpha,gamma-diaminobutyric acid (A2bu) in place of Lys4, were synthesized. All compounds displayed high mu receptor selectivity in the rat and guinea pig brain membrane binding assays and most of them were more potent mu agonists than DALDA in the mu receptor-representative guinea pig ileum assay, with [Dmt1]DALDA showing the highest potency. Because of its extraordinary mu agonist potency, high mu selectivity, polar character (charge of 3 + ) and metabolic stability, [Dmt1]DALDA has potential for use in obstetrical or peripheral analgesia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11121615     DOI: 10.1016/s0223-5234(00)01171-5

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  50 in total

1.  Bifunctional μ/δ opioid peptides: variation of the type and length of the linker connecting the two components.

Authors:  Jinguo Ding; Carole Lemieux; Nga N Chung; Peter W Schiller
Journal:  Chem Biol Drug Des       Date:  2012-01-04       Impact factor: 2.817

Review 2.  In vitro and direct in vivo testing of mixture-based combinatorial libraries for the identification of highly active and specific opiate ligands.

Authors:  Richard A Houghten; Colette T Dooley; Jon R Appel
Journal:  AAPS J       Date:  2006-05-26       Impact factor: 4.009

3.  Design, synthesis and evaluation of 111In labeled DOTA-conjugated tetrapeptides having high affinity and selectivity for mu opioid receptors.

Authors:  John R Lever; Emily A Fergason-Cantrell; Terry L Carmack; Lisa D Watkinson; Fabio Gallazzi
Journal:  Nucl Med Biol       Date:  2019-03-07       Impact factor: 2.408

4.  Mast Cell Degranulation and Fibroblast Activation in the Morphine-induced Spinal Mass: Role of Mas-related G Protein-coupled Receptor Signaling.

Authors:  Tony L Yaksh; Kelly A Eddinger; Shinichi Kokubu; Zhenping Wang; Anna DiNardo; Roshni Ramachandran; Yuelian Zhu; Yajun He; Fieke Weren; Daphne Quang; Shelle A Malkmus; Katherine Lansu; Wesley K Kroeze; Brian Eliceiri; Joanne J Steinauer; Peter W Schiller; Peter Gmeiner; Linda M Page; Keith R Hildebrand
Journal:  Anesthesiology       Date:  2019-07       Impact factor: 7.892

5.  Differential analgesic effects of a mu-opioid peptide, [Dmt(1)]DALDA, and morphine.

Authors:  Megumi Shimoyama; Hazel H Szeto; Peter W Schiller; Yugo Tagaito; Hideyuki Tokairin; Chong moon Eun; Naohito Shimoyama
Journal:  Pharmacology       Date:  2008-11-06       Impact factor: 2.547

Review 6.  Novel therapies targeting inner mitochondrial membrane--from discovery to clinical development.

Authors:  Hazel H Szeto; Peter W Schiller
Journal:  Pharm Res       Date:  2011-06-03       Impact factor: 4.200

7.  Design of novel neurokinin 1 receptor antagonists based on conformationally constrained aromatic amino acids and discovery of a potent chimeric opioid agonist-neurokinin 1 receptor antagonist.

Authors:  Steven Ballet; Debby Feytens; Koen Buysse; Nga N Chung; Carole Lemieux; Suneeta Tumati; Attila Keresztes; Joost Van Duppen; Josephine Lai; Eva Varga; Frank Porreca; Peter W Schiller; Jozef Vanden Broeck; Dirk Tourwé
Journal:  J Med Chem       Date:  2011-03-17       Impact factor: 7.446

8.  Psychedelics and the human receptorome.

Authors:  Thomas S Ray
Journal:  PLoS One       Date:  2010-02-02       Impact factor: 3.240

Review 9.  Bi- or multifunctional opioid peptide drugs.

Authors:  Peter W Schiller
Journal:  Life Sci       Date:  2009-03-11       Impact factor: 5.037

10.  Mitochondria-targeted small molecule SS31: a potential candidate for the treatment of Alzheimer's disease.

Authors:  P Hemachandra Reddy; Maria Manczak; Ramesh Kandimalla
Journal:  Hum Mol Genet       Date:  2017-04-15       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.